Cargando…

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and immunosuppressive therapy (IST) are two major competing treatment strategies for acquired aplastic anemia (AA). Whether allo-HSCT is superior to IST as a front-line treatment for patients with AA has been a subject of deb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yangmin, Gao, Qingyan, Hu, Jing, Liu, Xu, Guan, Dongrui, Zhang, Fengkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059290/ https://www.ncbi.nlm.nih.gov/pubmed/32138642 http://dx.doi.org/10.1186/s12865-020-0340-x

Ejemplares similares

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

Immunosuppressive Treatment in Children with Acquired Aplastic Anemia
por: Yıldırmak, Yıldız, et al.
Publicado: (2012)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

P1317: TIME-DEPENDENT ANALYSIS OF THE IMPACT ON EARLY CMV REACTIVATION OF HLA MISMATCH AND ACUTE GRAFT-VERSUS-HOST-DISEASE AFTER ALLO-HSCT FROM RELATED DONORS IN ACQUIRED APLASTIC ANEMIA.
por: Lin, Fan, et al.
Publicado: (2023)

Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia
por: Dong, Peiyuan, et al.
Publicado: (2022)

Aplastic anemia: immunosuppressive therapy in 2010
por: Risitano, Antonio M., et al.
Publicado: (2011)

Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
por: Liu, Zenghui, et al.
Publicado: (2020)

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis
por: Yang, Apeng, et al.
Publicado: (2019)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: A meta-analysis of retrospective studies
por: Wang, Jia, et al.
Publicado: (2020)

Gut inflammation in the pathogenesis of acquired aplastic anemia
por: Zhao, Xi-Chen, et al.
Publicado: (2020)

First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
por: Peinemann, Frank, et al.
Publicado: (2011)

Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia
por: Chen, Hai-Fei, et al.
Publicado: (2014)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022)

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis−associated aplastic anemia
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

THPO gene variants in patients with acquired aplastic anemia
por: Padilha, Pedro Henrique, et al.
Publicado: (2018)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
por: Gao, Xuan, et al.
Publicado: (2022)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Thymoma followed by aplastic anemia - two different responses to immunosuppressive therapy
por: de Castro, Murilo Antunes, et al.
Publicado: (2011)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
por: Liu, Limin, et al.
Publicado: (2022)

Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment
por: Medinger, Michael, et al.
Publicado: (2018)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report
por: Matsui, Kenji, et al.
Publicado: (2022)

Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Limin, et al.
Publicado: (2021)

Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study
por: Jalaeikhoo, Hasan, et al.
Publicado: (2015)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Traditional Chinese medicine for treating aplastic anemia
por: Guan, Jing, et al.
Publicado: (2023)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes
por: Giudice, Valentina, et al.
Publicado: (2018)

Acquired Aplastic Anemia as a Clonal Disorder of Hematopoietic Stem Cells
por: Brzeźniakiewicz-Janus, Katarzyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qbc78vrb3r21l47s63a8iork49